Targeting IL-6 for the treatment of rheumatoid arthritis: Phase II investigational drugs

Bibliography

• Boissier MC, Semerano L, Challal S, et al. Rheumatoid arthritis: from autoimmunity to synovitis and joint destruction. J Autoimmun 2012;39:222-8
   PubMed Web of Science ®Google Scholar
• Gaujoux-Viala C, Nam J, Ramiro S, et al. Efficacy of conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis 2014;73:510-15
   PubMed Web of Science ®Google Scholar
• Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014;73:492-509
   PubMed Web of Science ®Google Scholar
• Smolen JS, Aletaha D, Bijlsma WJ, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69:631-7
   PubMed Web of Science ®Google Scholar
• Taylor PC, Feldmann M. Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis. Nat Rev Rheumatol 2009;5:578-82
   PubMed Web of Science ®Google Scholar
• Falgarone G, Semerano L, Rullé S, et al. Targeting lymphocyte activation to treat rheumatoid arthritis. Joint Bone Spine 2009;76:327-32
   PubMed Web of Science ®Google Scholar
• Yazici Y. Rheumatoid arthritis: when should we use rituximab to treat RA? Nat Rev Rheumatol 2011;7:379-80
   PubMed Web of Science ®Google Scholar
• Ash Z, Emery P. The role of tocilizumab in the management of rheumatoid arthritis. Expert Opin Biol Ther 2012;12:1277-89
   PubMed Web of Science ®Google Scholar
• Burmester GR, Rubbert-Roth A, Cantagrel A, et al. A randomized, double blind, parallel group study of the safety and efficacy of tocilizumab SC versus tocilizumab IV, in combination with traditional DMARDs in patient with moderate to severe RA. Arthritis Rheum 2012;64:S1075
   Web of Science ®Google Scholar
• Smolen JS, Schoels MM, Nishimoto N, et al. Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. Ann Rheum Dis 2013;72:482-92
   PubMed Web of Science ®Google Scholar
• Smolen JS, Beaulieu A, Rubbert-Roth A, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 2008;371(9617):987-97
   PubMed Web of Science ®Google Scholar
• Genovese MC, McKay JD, Nasonov EL, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 2011;63:2854-64
   PubMed Web of Science ®Google Scholar
• Emery P, Keystone E, Tony HP, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 2008;67:1516-23
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Miyasaka N, Yamamoto K, et al. Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study. Ann Rheum Dis 2009;68:1580-4
   PubMed Web of Science ®Google Scholar
• Kremer JM, Blanco R, Brzosko M, et al. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. Arthritis Rheum 2011;63:609-21
   PubMed Web of Science ®Google Scholar
• Jones G, Sebba A, Gu J, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis 2010;69:88-96
   PubMed Web of Science ®Google Scholar
• Dougados M, Kissel K, Sheeran T, et al. Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY). Ann Rheum Dis 2013;72:43-50
   PubMed Web of Science ®Google Scholar
• Gabay C, Emery P, van Vollenhoven R, et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet 2013;381(9877):1541-50
   PubMed Web of Science ®Google Scholar
• Kishimoto T. IL-6: from its discovery to clinical applications. Int Immunol 2010;22:347-52
   PubMed Web of Science ®Google Scholar
• Jones SA, Scheller J, Rose-John S. Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. J Clin Invest 2011;121:3375-83
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Kishimoto T. Interleukin 6: from bench to bedside. Nat Clin Pract Rheumatol 2006;2:619-26
   PubMedGoogle Scholar
• Walker JG, Smith MD. The Jak-STAT pathway in rheumatoid arthritis. J Rheumatol 2005;32:1650-3
   PubMed Web of Science ®Google Scholar
• Silke J. The regulation of TNF signalling: what a tangled web we weave. Curr Opin Immunol 2011;23:620-6
   PubMed Web of Science ®Google Scholar
• Choy EH, Kavanaugh AF, Jones SA. The problem of choice: current biologic agents and future prospects in RA. Nat Rev Rheumatol 2013;9:154-63
   PubMed Web of Science ®Google Scholar
• Drucker C, Gewiese J, Malchow S, et al. Impact of interleukin-6 classic- and trans-signaling on liver damage and regeneration. J Autoimmun 2010;34:29-37
   Google Scholar
• Scheller J, Grötzinger J, Rose-John S. Updating interleukin-6 classic- and trans-signaling. Signal Transduct 2006;6:240-59
   Google Scholar
• Yoshida Y, Tanaka T. Interleukin 6 and rheumatoid arthritis. BioMed Res Int 2014;2014:698313
   PubMed Web of Science ®Google Scholar
• Rose-John S. IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6. Int J Biol Sci 2012;8(9):1237-47
   PubMed Web of Science ®Google Scholar
• Hirota K, Hashimoto M, Yoshitomi H, et al. T cell self-reactivity forms a cytokine milieu for spontaneous development of IL-17+ Th cells that cause autoimmune arthritis. J Exp Med 2007;204:41-7
   PubMed Web of Science ®Google Scholar
• Clavel G, Thiolat A, Boissier MC. Interleukin newcomers creating new numbers in rheumatology: IL-34 to IL-38. Joint Bone Spine 2013;80:449-53
   PubMed Web of Science ®Google Scholar
• Miossec P, Korn T, Kuchroo VK. Interleukin-17 and type 17 helper T cells. N Engl J Med 2009;361:888-98
   PubMed Web of Science ®Google Scholar
• Huizinga TWJ, Fleischmann RM, Jasson M, et al. Sarilumab, a fully human monoclonal antibody against IL-6Rα in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial. Ann Rheum Dis 2013; Published Online First: 2 December 2013
   Google Scholar
• Sanofi and Regeneron Report Positive Results with Sarilumab in First Phase 3 Rheumatoid Arthritis Registration Trial. The Wall Street Journal. Available from: http://online.wsj.com/article/PR-CO-20131122-900052.html
   Google Scholar
• Van Roy M, Ulrichts H, Rossenu S, et al. Preclinical development of ALX-0061, an anti-IL-6R nanobody for therapeutic use in rheumatoid arthritis with a high in vitro affinity and potency and a competitive in vivo pharmacological profile [abstract]. Arthritis Rheum 2012;64(Suppl 10):336
   Google Scholar
• De Bruyn S, Gachalyi B, Rojkovich B, et al. Anti-IL-6 receptor nanobody (ALX-0061) seamless first-in-human phase I/II POC study in patients with active RA on stable MTX treatment [abstract]. Arthritis Rheum 2012;64(Suppl 10):1307
   Google Scholar
• Hsu B, Sheng S, Weinblatt ME, et al. Results from a multicenter international, randomized, double-blind, international, randomized, double-blind, placebo-controlled, phase 2 study of sirukumab, a human anti-IL-6 monoclonal antibody, in patients with active rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis 2013;71:61
   Web of Science ®Google Scholar
• Finch DK, Sleeman MA, Moisan J, et al. Whole-molecule antibody engineering: generation of a high-affinity anti-IL-6 antibody with extended pharmacokinetics. J Mol Biol 2011;411:791-807
   PubMed Web of Science ®Google Scholar
• Moisan J, Faggioni R, Liang M, et al. MEDI5117: a human high affinity anti-IL-6 monoclonal antibody with enhanced serum half-life in development for the treatment of inflammation and rheumatological diseases [abstract]. Arthritis Rheum 2009;60(Suppl 10):401
   Google Scholar
• Study to Assess the Safety and Tolerability of MEDI5117 in Rheumatoid Arthritis Patients. ClinicalTrials.gov. Available from: http://clinicaltrials.gov/ct2/results?term=MEDI5117&Search=Search
   Google Scholar
• Mease P, Strand V, Shalamberidze L, et al. A phase II, double-blind, randomised, placebo-controlled study of BMS945429 (ALD518) in patients with rheumatoid arthritis with an inadequate response to methotrexate. Ann Rheum Dis 2012;71:1183-9
   PubMed Web of Science ®Google Scholar
• Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate. ClinicalTrials.gov. Available from: http://clinicaltrials.gov/ct2/show/NCT01373151?term=BMS945429&rank=3
   Google Scholar
• Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis. Available from: http://clinicaltrials.gov/ct2/show/NCT02015520?term=BMS945429&rank=4
   Google Scholar
• Fleischmann R, Kivitz A, Wagner F, et al. A pilot study investigating the tolerability and pharmacodynamic effect of single intravenous/subcutaneous doses of olokizumab, an anti-interleukin-6 monoclonal antibody, in patients with rheumatoid arthritis [abstract]. Arthritis Rheum 2012;64(Suppl 10):1339
   Google Scholar
• UCB announces top-line phase 2 results for olokizumab in rheumatoid arthritis. UCB. www.ucb.com. Available from: http://www.ucb.presscentre.com/News/UCB-announces-top-line-phase-2-results-for-olokizumab-in-rheumatoid-arthritis-31e.aspx
   Google Scholar
• Ferring and Conaris complete license agreement for new recombinant molecule in gastroenterology.www.ferring.com. Available from: http://www.ferring.com/en/media/press-releases/2008/ferringplusandplusconarispluscompletepluslicenseplusagreementplusforplusnewplusrecombinantplusmoleculeplusinplusgastroenterology.aspx
   Google Scholar
• Rafique A, Martin J, Blome M, et al. Evaluation of the binding kinetics and functional bioassay activity of sarilumab and tocilizumab to the human il-6 receptor (il-6r) alpha. Ann Rheum Dis 2013;72(Suppl 3):A797
   PubMedGoogle Scholar
• Belomestnov P, Hamilton J, DiCioccio AT, et al. Sarilumab, a subcutaneously-administered, fully-human monoclonal antibody inhibitor of the IL-6 receptor: pharmacokinetic profile and its relationship to changes in pharmacodynamic markers in patients with rheumatoid arthritis. Arthritis Rheum 2012;64:S576
   Web of Science ®Google Scholar
• Genovese MC, Fleischmann RM, Fiore S, et al. Sarilumab, a subcutaneously-administered, fully-human monoclonal antibody inhibitor of the IL-6 receptor: relationship between EULAR responses and change from baseline of selected clinical parameters. Ann Rheum Dis 2013;72:A620
   Web of Science ®Google Scholar
• Genovese MC, Fleischmann RM, Jasson M, et al. Sarilumab, a subcutaneously-administered, fully-human monoclonal antibody inhibitor of the IL-6 receptor: effects on hemoglobin levels in a clinical trial for the treatment of moderate-to-severe rheumatoid arthritis [abstract]. Arthritis Rheum 2012;64(Suppl 10):1320
   Google Scholar
• Effect of SAR153191 (REGN88) With Methotrexate in Patients With Active Rheumatoid Arthritis Who Failed TNF-α Blockers. ClinicalTrail.gov. Available from: http://clinicaltrials.gov/ct2/show/NCT01217814?term=sarilumab&rank=6
   Google Scholar
• Long Term Evaluation of SAR153191 (REGN88, Sarilumab) on Top of Disease Modifying Anti-rheumatic Drugs in Rheumatoid Arthritis Patients (RA-EXTEND) ClinicalTrail.gov. Available from: http://clinicaltrials.gov/ct2/show/NCT011?term=sarilumab&rank=11
   Google Scholar
• To Evaluate The Effect Of SAR153191 (REGN88) Added To Other RA Drugs In Patients With RA Who Are Not Responding To Or Intolerant Of Anti-TNF Therapy (SARIL-RA-TARGET). ClinicalTrail.gov. Available from: http://clinicaltrials.gov/ct2/show/NCT01709578?term=sarilumab&rank=8
   Google Scholar
• To Evaluate The Safety of SAR153191 (REGN88) and Tocilizumab Added to Other RA Drugs in Patients With RA Who Are Not Responding to or Intolerant of Anti-TNF Therapy (SARIL-RA-ASCERTAIN). ClinicalTrail.gov. Available from: http://clinicaltrials.gov/ct2/show/NCT01768572?term=sarilumab&rank=10
   Google Scholar
• An Evaluation of Sarilumab Plus Methotrexate Compared to Etanercept Plus Methotrexate in RA Patients Not Responding to Adalimumab Plus Methotrexate (RA-COMPARE). ClinicalTrail.gov. Available from: http://clinicaltrials.gov/ct2/show/NCT01764997?term=sarilumab&rank=5
   Google Scholar
• Beck A, Thierry Wurch T, Bailly C, et al. Strategies and challenges for the next generation of therapeutic antibodies. Nat Rev Immunol 2010;10:345-52
   PubMed Web of Science ®Google Scholar
• Van Roy M, Van de Sompel A, De Smet K, et al. ALX-001, an anti-IL6R nanobody for therapeutic use in rheumatoid arthritis, demonstrates in vitro a differential biological activity profile as compared to tocilizumab. Ann Rheum Dis 2013;72:A375
   Web of Science ®Google Scholar
• Van Roy M, Ulrichts H, Rossenu S, et al. Preclinical development of ALX-0061, an anti-IL-6R nanobody for therapeutic use in rheumatoid arthritis with a high in vitro affinity and potency and a competitive in vivo pharmacological profile [abstract]. Arthritis Rheum 2012;64(Suppl 10):336
   Google Scholar
• Holz JB, Sargentini-Maier L, De Bruyn S, et al. Twenty-four weeks of treatment with a novel anti-IL6 receptor nanobody (ALX-0061) resulted in 84% ACR20 improvement and 58% DAS28 remission in a phase I/II study in RA. Ann Rheum Dis 2013;72:A64
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Terao K, Mima T, et al. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood 2008;112:3959-64
   PubMed Web of Science ®Google Scholar
• Ablynx And AbbVie Sign Global License Agreement For anti-IL-6R Nanobody, ALX-0061, To Treat Inflammatory Diseases. PR Newswire. Available from: http://www.prnewswire.com/news-releases/ablynx-and-abbvie-sign-global-license-agreement-for-anti-il-6r-nanobody-alx-0061-to-treat-inflammatory-diseases-224815952.html
   Google Scholar
• Hsu B, Sheng S, Smolen JS, et al. Results from a 2-part, proof-of-concept, dose-ranging, randomized, double-blind, placebo-controlled, phase 2 study of sirukumab, a human anti-IL-6 monoclonal antibody, in patients with active rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis 2013;71:188
   Web of Science ®Google Scholar
• Xu Z, Bouman-Thio E, Comisar C, et al. Pharmacokinetics, pharmacodynamics and safety of a human anti-IL-6 monoclonal antibody (sirukumab) in healthy subjects in a first-in-human study. Br J Clin Pharmacol 2011;72:270-81
   PubMed Web of Science ®Google Scholar
• Tabrizi MA, Tseng CM, Roskos LK. Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discov Today 2006;11:81-8
   PubMed Web of Science ®Google Scholar
• Frey N, Grange S, Woodworth T. Population pharmacokinetic analysis of tocilizumab in patients with rheumatoid arthritis. J Clin Pharmacol 2010;50:754-6
   PubMed Web of Science ®Google Scholar
• Zhuang Y, Xu Z, de Vries DE, et al. Pharmacokinetics and safety of sirukumab following a single subcutaneous administration to healthy Japanese and Caucasian subjects. Int J Clin Pharmacol Ther 2013;51:187-99
   PubMed Web of Science ®Google Scholar
• Hsu B, Sheng S, Weinblatt ME, et al. Results from a 2- multicenter, international, randomized, double-blind, placebo-controlled, phase 2 study of sirukumab, a human anti-IL-6 monoclonal antibody, in patients with active rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis 2013;71:61
   Web of Science ®Google Scholar
• Hsu B, Sheng S, Smolen J, et al. Results from a 2-part, proof-of-concept, dose-ranging, randomized, double-blind, placebo-controlled, phase 2 study of sirukumab, a human anti-interleukin-6 monoclonal antibody, in active rheumatoid arthritis patients despite methotrexate therapy [abstract]. Arthritis Rheum 2011;63(Suppl 10):2631
   Google Scholar
• Hsu B, Chiou CF, Sheng S, et al. Sirukumab, a human anti-IL-6 monoclonal antibody, improves physical function in patients with active rheumatoid arthritis despite methotrexate therapy: results from a 2-part, proof-of-concept, dose-ranging, randomized, double-blind, placebo-controlled, phase 2 study. Ann Rheum Dis 2013;71:373
   Web of Science ®Google Scholar
• Hsu B. Results from a multicenter, international, randomized, double-blind, placebo-controlled, phase 2 study of sirukumab, a human anti-IL-6 monoclonal antibody, in patients with active rheumatoid arthritis despite methotrexate therapy [abstract]. Arthritis Rheum 2011;63(Suppl 10):2632
   Google Scholar
• Toedter G, Sague S, Wu X, et al. Effect of sirukumab on hepcidin levels and markers of anemia: results of a phase 2b trial in patients with active rheumatoid arthritis despite methotrexate therapy [abstract]. Arthritis Rheum 2011;63(Suppl 10):415
   Google Scholar
• A Study of CNTO 136 (Sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Anti-TNF-Alpha Therapy (SIRROUND). ClinicalTrail.gov. Available from: http://clinicaltrials.gov/ct2/show/NCT01606761?term=sirukumab&rank=2
   Google Scholar
• A Study of CNTO 136 (Sirukumab), Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Disease-Modifying Antirheumatic Drug (DMARD) Therapy (SIRROUND). ClinicalTrail.gov. Available from: http://clinicaltrials.gov/ct2/show/NCT01604343?term=sirukumab&rank=5
   Google Scholar
• Long-term Safety and Efficacy of Sirukumab in Participants With RA Completing Studies CNTO136ARA3002 or CNTO136ARA3003 (SIRROUND-LTE). ClinicalTrail.gov. Available from: http://clinicaltrials.gov/ct2/show/NCT01856309?term=sirukumab&rank=4
   Google Scholar
• A Study Comparing Sirukumab (CNTO 136) Monotherapy With Adalimumab (HUMIRA®) Monotherapy in the Treatment of Active Rheumatoid Arthritis. ClinicalTrail.gov. Available from: http://clinicaltrials.gov/ct2/show/NCT02019472?term=sirukumab&rank=3
   Google Scholar
• Study to Assess the Safety and Tolerability of MEDI5117 in Rheumatoid Arthritis Patients. ClinicalTrail.gov. Available from: http://clinicaltrials.gov/ct2/show/NCT01559103?term=MEDI5117&rank=1
   Google Scholar
• Shakib S, Francis B, Smith J. Safety, pharmacokinetics and pharmacodynamics of ALD518 (BMS-945429), a high-affinity monoclonal antibody directed against interleukin-6 (IL-6) administered by subcutaneous injection: a phase I trial [abstract]. Arthritis Rheum 2010;62(Suppl 10):1124
   Google Scholar
• Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate. ClinicalTrail.gov. Available from: http://clinicaltrials.gov/ct2/show/NCT01373151?term=NCT01373151&rank=1
   Google Scholar
• Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis. ClinicalTrail.gov. Available from: http://clinicaltrials.gov/ct2/show/NCT02015520?term=NCT02015520&rank=1
   Google Scholar
• Russia's R-Pharm to develop UCB's olokizumab for rheumatoid arthritis. The Pharma Letter. Available from: http://www.thepharmaletter.com/article/russia-s-r-pharm-to-develop-ucb-s-olokizumab-for-rheumatoid-arthritis
   Google Scholar
• Nowell MA, Williams AS, Carty SA, et al. Therapeutic targeting of IL-6 trans signaling counteracts STAT3 control of experimental inflammatory arthritis. J Immunol 2009;182:613-22
   PubMed Web of Science ®Google Scholar
• Actemra. Risk Evaluation and Mitigation Strategy (REMS). Food and Drug Administration. Available from: http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM202044.pdf
   Google Scholar
• Grivennikov S, Karin E, Terzic J, et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 2009;15:103-13. Erratum in: Cancer Cell. 2009;15:241
   PubMed Web of Science ®Google Scholar
• Fernandes TJ, Hodge JM, Singh PP, et al. Cord blood-derived macrophage-lineage cells rapidly stimulate osteoblastic maturation in mesenchymal stem cells in a glycoprotein-130 dependent manner. PLoS One 2013;8:e73266
   PubMed Web of Science ®Google Scholar
• Smolen JS, Schoels MM, Nishimoto N, et al. Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. Ann Rheum Dis 2013;72:482-92
   PubMed Web of Science ®Google Scholar
• Samson M, Audia S, Janikashvili N, et al. Brief report: inhibition of interleukin-6 function corrects Th17/Treg cell imbalance in patients with rheumatoid arthritis. Arthritis Rheum 2012;64:2499-503
   PubMed Web of Science ®Google Scholar
• Thiolat A, Semerano L, Pers YM, et al. Interleukin-6 receptor blockade enhances CD39+ regulatory T cell development in rheumatoid arthritis and in experimental arthritis. Arthritis Rheumatol 2014;66:273-83
   PubMed Web of Science ®Google Scholar
• McInnes IB, Thompson L, Giles JT, et al. Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study. Ann Rheum Dis 2013. [ Epub ahead of print]
   Google Scholar
• Fielding CA, McLoughlin RM, McLeod L, et al. IL-6 regulates neutrophil trafficking during acute inflammation via STAT3. J Immunol 2008;181:2189-95
   PubMed Web of Science ®Google Scholar
• Dougados M. Do we need therapeutic trials comparing biotherapies to guide treatment selection in patients with rheumatoid arthritis? Joint Bone Spine 2013;80:443-5
   PubMed Web of Science ®Google Scholar